Candidate rotavirus vaccine (rhesus rotavirus strain) in children: an evaluation.
Fifty children, 3 months to 12 years of age, were given an experimental, orally administered, live attenuated rotavirus vaccine. Overall evidence of vaccine effectiveness as judged by vaccine virus shedding or a serologic response was seen in 82% of vaccinees. No clinical illness was seen in the rotavirus vaccinees when compared with 40 concurrently studied control children. No transmission to control children was observed even with close daily contact in a day-care setting. Young infants, generally less than 1 year of age, who had not previously experienced wild-type rotavirus infection shed significantly more vaccine virus. Limitation of virus shedding in those already exposed may be related to a prompt copro-IgA response which was significantly elevated by three days after vaccination. In summary, the development of this rotavirus vaccine, rhesus rotavirus-MMU-18006, is a promising step in the development of immunoprophylaxis against this major enteric pathogen.
Wright
P F
PF
Department of Pediatrics, Vanderbilt University, Nashville, TN 37232.
Tajima
T
T
Thompson
J
J
Kokubun
K
K
Kapikian
A
A
Karzon
D T
DT
D000914:Antibodies, Viral / Q000096:biosynthesis; D002648:Child; D002675:Child, Preschool; D005243:Feces / Q000276:immunology / Q000382:microbiology; D005334:Fever / Q000209:etiology; D005767:Gastrointestinal Diseases / Q000517:prevention & control; D006801:Humans; D007223:Infant; D011159:Population Surveillance; D011897:Random Allocation; D012401:Rotavirus / Q000276:immunology* / Q000302:isolation & purification; D012400:Rotavirus Infections / Q000517:prevention & control*; D014613:Vaccines, Attenuated / Q000009:adverse effects / Q000276:immunology
D000914:Antibodies, Viral; D014613:Vaccines, Attenuated